IL166552A0 - Pyrimidine derivatives and their use as cb2 modulators - Google Patents
Pyrimidine derivatives and their use as cb2 modulatorsInfo
- Publication number
- IL166552A0 IL166552A0 IL16655205A IL16655205A IL166552A0 IL 166552 A0 IL166552 A0 IL 166552A0 IL 16655205 A IL16655205 A IL 16655205A IL 16655205 A IL16655205 A IL 16655205A IL 166552 A0 IL166552 A0 IL 166552A0
- Authority
- IL
- Israel
- Prior art keywords
- modulators
- pyrimidine derivatives
- pyrimidine
- derivatives
- Prior art date
Links
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0219501A GB0219501D0 (en) | 2002-08-21 | 2002-08-21 | Compounds |
GB0309326A GB0309326D0 (en) | 2003-04-24 | 2003-04-24 | Compounds |
PCT/EP2003/009217 WO2004018433A1 (en) | 2002-08-21 | 2003-08-19 | Pyrimidine derivatives and their use as cb2 modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
IL166552A0 true IL166552A0 (en) | 2006-01-15 |
Family
ID=31948030
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16655205A IL166552A0 (en) | 2002-08-21 | 2005-01-27 | Pyrimidine derivatives and their use as cb2 modulators |
IL185549A IL185549A0 (en) | 2002-08-21 | 2007-08-27 | Pyrimidine derivatives and their use as cb2 modulators |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL185549A IL185549A0 (en) | 2002-08-21 | 2007-08-27 | Pyrimidine derivatives and their use as cb2 modulators |
Country Status (35)
Country | Link |
---|---|
US (2) | US7635701B2 (ru) |
EP (2) | EP1878725B1 (ru) |
JP (1) | JP4583174B2 (ru) |
KR (1) | KR20050058367A (ru) |
CN (1) | CN100351239C (ru) |
AP (1) | AP2005003219A0 (ru) |
AR (1) | AR041016A1 (ru) |
AT (2) | ATE489369T1 (ru) |
AU (1) | AU2003264076B2 (ru) |
BR (1) | BR0313676A (ru) |
CA (1) | CA2495880C (ru) |
CY (1) | CY1107871T1 (ru) |
DE (2) | DE60317348T2 (ru) |
DK (1) | DK1539712T3 (ru) |
EA (2) | EA010130B1 (ru) |
EC (1) | ECSP055613A (ru) |
ES (1) | ES2295682T3 (ru) |
HK (1) | HK1079193A1 (ru) |
IL (2) | IL166552A0 (ru) |
IS (1) | IS7749A (ru) |
MA (1) | MA27428A1 (ru) |
MX (1) | MXPA05001960A (ru) |
MY (1) | MY137053A (ru) |
NO (1) | NO20051451D0 (ru) |
NZ (1) | NZ537886A (ru) |
OA (1) | OA12910A (ru) |
PE (1) | PE20040898A1 (ru) |
PL (1) | PL376047A1 (ru) |
PT (1) | PT1539712E (ru) |
SI (1) | SI1539712T1 (ru) |
TW (1) | TW200410946A (ru) |
UA (1) | UA83194C2 (ru) |
UY (1) | UY27939A1 (ru) |
WO (1) | WO2004018433A1 (ru) |
ZA (1) | ZA200500913B (ru) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY27939A1 (es) * | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | Compuestos |
US7405221B2 (en) | 2002-09-27 | 2008-07-29 | Merck & Co., Inc. | Substituted pyrimidines |
AR043633A1 (es) | 2003-03-20 | 2005-08-03 | Schering Corp | Ligandos de receptores de canabinoides |
US20040259887A1 (en) * | 2003-06-18 | 2004-12-23 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
GB0402355D0 (en) * | 2004-02-03 | 2004-03-10 | Glaxo Group Ltd | Novel compounds |
GB0402356D0 (en) * | 2004-02-03 | 2004-03-10 | Glaxo Group Ltd | Novel compounds |
NZ551027A (en) | 2004-04-08 | 2011-01-28 | Targegen Inc | Benzotriazine inhibitors of kinases |
MX2007002208A (es) | 2004-08-25 | 2007-05-08 | Targegen Inc | Compuestos hetrociclicos y metodos de uso. |
GB0517188D0 (en) * | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
US8604042B2 (en) | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
HUE028987T2 (en) | 2005-11-01 | 2017-01-30 | Targegen Inc | BI-aryl-meta-pyrimidine inhibitors of kinases |
US8133900B2 (en) | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
EP1966132A2 (en) | 2005-12-15 | 2008-09-10 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
WO2007118041A1 (en) * | 2006-04-07 | 2007-10-18 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
CA2657247A1 (en) | 2006-07-28 | 2008-01-31 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
WO2008032764A1 (fr) * | 2006-09-13 | 2008-03-20 | Kyowa Hakko Kirin Co., Ltd. | Dérivé hétérocyclique fusionné |
JP5030114B2 (ja) | 2006-09-25 | 2012-09-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cb2受容体をモジュレートする化合物 |
MX2009003316A (es) * | 2006-10-04 | 2009-04-09 | Hoffmann La Roche | Derivados de pirazina-2-carboxamida como moduladores receptores de cb2. |
WO2008048914A1 (en) * | 2006-10-17 | 2008-04-24 | Boehringer Ingelheim International Gmbh | Polycyclic compounds which modulate the cb2 receptor |
WO2008075353A1 (en) | 2006-12-19 | 2008-06-26 | Pharmos Corporation | Sulfonamide derivatives with therapeutic indications |
GB0705803D0 (en) * | 2007-03-28 | 2007-05-02 | Glaxo Group Ltd | Novel compounds |
AU2008323877A1 (en) * | 2007-11-06 | 2009-05-14 | Emory University | Methods of identifying safe NMDA receptor antagonists |
EP2217565B1 (en) | 2007-11-07 | 2013-05-22 | Boehringer Ingelheim International GmbH | Compounds which modulate the cb2 receptor |
WO2010005782A1 (en) | 2008-07-10 | 2010-01-14 | Boehringer Ingelheim International Gmbh | Sulfone compounds which modulate the cb2 receptor |
JP5453437B2 (ja) | 2008-09-25 | 2014-03-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cb2受容体を選択的に調節するスルホニル化合物 |
TW201031650A (en) * | 2008-12-02 | 2010-09-01 | Organon Nv | 1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione |
TW201031649A (en) | 2008-12-02 | 2010-09-01 | Organon Nv | 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives |
EP2415765A4 (en) * | 2009-03-30 | 2012-08-15 | Astellas Pharma Inc | PYRIMIDINE COMPOUND |
US8299103B2 (en) | 2009-06-15 | 2012-10-30 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
JP5756800B2 (ja) | 2009-06-16 | 2015-07-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cb2受容体を調節するアゼチジン2−カルボキサミド誘導体 |
EP2480544A1 (en) | 2009-09-22 | 2012-08-01 | Boehringer Ingelheim International GmbH | Compounds which selectively modulate the cb2 receptor |
EP2523936A1 (en) | 2010-01-15 | 2012-11-21 | Boehringer Ingelheim International GmbH | Compounds which modulate the cb2 receptor |
WO2011109324A1 (en) | 2010-03-05 | 2011-09-09 | Boehringer Ingelheim International Gmbh | Tetrazole compounds which selectively modulate the cb2 receptor |
WO2012012307A1 (en) | 2010-07-22 | 2012-01-26 | Boehringer Ingelheim International Gmbh | Sulfonyl compounds which modulate the cb2 rece |
EP2599774B1 (en) * | 2010-07-29 | 2016-07-06 | Astellas Pharma Inc. | Condensed pyridine compounds as cb2 cannabinoid receptor ligands |
CA2816957A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
US20150261260A1 (en) * | 2013-03-15 | 2015-09-17 | Royce J. Nicholas | Method of water-proofing electronic components |
EP2803668A1 (en) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
AU2014340114B2 (en) * | 2013-10-23 | 2018-10-18 | Academia Sinica | Compounds for use in prevention and treatment of neurodegenerative diseases and pain |
WO2017185038A1 (en) | 2016-04-22 | 2017-10-26 | Receptor Life Sciences | Fast-acting plant-based medicinal compounds and nutritional supplements |
EA201892396A1 (ru) | 2016-12-02 | 2019-04-30 | Ресептор Лайф Сайенсиз, Инк. | Быстродействующие растительные лекарственные соединения и биологически активные добавки |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5518A (en) | 1848-04-18 | Geaijst-drieb | ||
US4826689A (en) | 1984-05-21 | 1989-05-02 | University Of Rochester | Method for making uniformly sized particles from water-insoluble organic compounds |
FR2634376B1 (fr) | 1988-07-21 | 1992-04-17 | Farmalyoc | Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation |
IT1227626B (it) | 1988-11-28 | 1991-04-23 | Vectorpharma Int | Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione |
US5112820A (en) | 1990-03-05 | 1992-05-12 | Sterling Drug Inc. | Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof |
IT1243390B (it) | 1990-11-22 | 1994-06-10 | Vectorpharma Int | Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione. |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US5552160A (en) | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
HUT63941A (en) * | 1992-05-15 | 1993-11-29 | Hoechst Ag | Process for producing 4-alkyl-substituted pyrimidine-5-carboxanilide derivatives, and fungicidal compositions comprising same |
ATE150297T1 (de) | 1992-06-10 | 1997-04-15 | Nanosystems Llc | Oberflaechenmodifizierte nsaid nanopartikeln |
FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
US5346702A (en) | 1992-12-04 | 1994-09-13 | Sterling Winthrop Inc. | Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization |
US5298262A (en) | 1992-12-04 | 1994-03-29 | Sterling Winthrop Inc. | Use of ionic cloud point modifiers to prevent particle aggregation during sterilization |
US5302401A (en) | 1992-12-09 | 1994-04-12 | Sterling Winthrop Inc. | Method to reduce particle size growth during lyophilization |
US5340564A (en) | 1992-12-10 | 1994-08-23 | Sterling Winthrop Inc. | Formulations comprising olin 10-G to prevent particle aggregation and increase stability |
US5336507A (en) | 1992-12-11 | 1994-08-09 | Sterling Winthrop Inc. | Use of charged phospholipids to reduce nanoparticle aggregation |
US5429824A (en) | 1992-12-15 | 1995-07-04 | Eastman Kodak Company | Use of tyloxapole as a nanoparticle stabilizer and dispersant |
US5352459A (en) | 1992-12-16 | 1994-10-04 | Sterling Winthrop Inc. | Use of purified surface modifiers to prevent particle aggregation during sterilization |
US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
AU692484B2 (en) * | 1993-10-12 | 1998-06-11 | Du Pont Pharmaceuticals Company | 1N-alkyl-N-arylpyrimidinamines and derivatives thereof |
US5466823A (en) | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
US5587143A (en) | 1994-06-28 | 1996-12-24 | Nanosystems L.L.C. | Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
US5585108A (en) | 1994-12-30 | 1996-12-17 | Nanosystems L.L.C. | Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays |
US5662883A (en) | 1995-01-10 | 1997-09-02 | Nanosystems L.L.C. | Microprecipitation of micro-nanoparticulate pharmaceutical agents |
US5560932A (en) | 1995-01-10 | 1996-10-01 | Nano Systems L.L.C. | Microprecipitation of nanoparticulate pharmaceutical agents |
US5665331A (en) | 1995-01-10 | 1997-09-09 | Nanosystems L.L.C. | Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers |
US5571536A (en) | 1995-02-06 | 1996-11-05 | Nano Systems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
US5560931A (en) | 1995-02-14 | 1996-10-01 | Nawosystems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
US5503723A (en) | 1995-02-08 | 1996-04-02 | Eastman Kodak Company | Isolation of ultra small particles |
US5622938A (en) | 1995-02-09 | 1997-04-22 | Nano Systems L.L.C. | Sugar base surfactant for nanocrystals |
US5518738A (en) | 1995-02-09 | 1996-05-21 | Nanosystem L.L.C. | Nanoparticulate nsaid compositions |
US5534270A (en) | 1995-02-09 | 1996-07-09 | Nanosystems Llc | Method of preparing stable drug nanoparticles |
US5591456A (en) | 1995-02-10 | 1997-01-07 | Nanosystems L.L.C. | Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer |
US5573783A (en) | 1995-02-13 | 1996-11-12 | Nano Systems L.L.C. | Redispersible nanoparticulate film matrices with protective overcoats |
WO1996025405A1 (en) | 1995-02-13 | 1996-08-22 | G.D. Searle & Co. | Substituted isoxazoles for the treatment of inflammation |
US5633272A (en) | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
US5510118A (en) | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
US5580579A (en) | 1995-02-15 | 1996-12-03 | Nano Systems L.L.C. | Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers |
US5747001A (en) | 1995-02-24 | 1998-05-05 | Nanosystems, L.L.C. | Aerosols containing beclomethazone nanoparticle dispersions |
US5565188A (en) | 1995-02-24 | 1996-10-15 | Nanosystems L.L.C. | Polyalkylene block copolymers as surface modifiers for nanoparticles |
US5718919A (en) | 1995-02-24 | 1998-02-17 | Nanosystems L.L.C. | Nanoparticles containing the R(-)enantiomer of ibuprofen |
US5811428A (en) | 1995-12-18 | 1998-09-22 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions |
CA2230894A1 (en) * | 1995-09-01 | 1997-03-13 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions |
UA57002C2 (ru) | 1995-10-13 | 2003-06-16 | Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. | Производное (метилсульфонил)фенил-2-(5н)-фуранона, фармацевтическая композиция и способ лечения |
AU709262B2 (en) | 1995-10-17 | 1999-08-26 | Board Of Regents, The University Of Texas System | Insoluble drug delivery |
FR2742148B1 (fr) * | 1995-12-08 | 1999-10-22 | Sanofi Sa | Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant |
TR199802049T2 (xx) | 1996-04-12 | 1999-01-18 | G.D.Searle & Co. | COX-2 Inhibit�rlerinin �nilac� olarak s�bstit�e edilmi� benzens�lfonamid t�revleri. |
AU723179B2 (en) | 1996-07-18 | 2000-08-17 | Merck Canada Inc. | Substituted pyridines as selective cyclooxygenase-2 inhibitors |
WO1998035666A1 (en) | 1997-02-13 | 1998-08-20 | Nanosystems Llc | Formulations of nanoparticle naproxen tablets |
CO4960662A1 (es) | 1997-08-28 | 2000-09-25 | Novartis Ag | Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados |
WO1999012930A1 (en) | 1997-09-05 | 1999-03-18 | Glaxo Group Limited | 2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their prepa ration and their use as cyclooxygenase 2 (cox-2) inhibitors |
US6022884A (en) * | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
IL140276A0 (en) | 1998-06-19 | 2002-02-10 | Rtp Pharma Inc | Processes to generate submicron particles of water-insoluble compounds |
EP2266542A3 (en) | 1998-10-01 | 2013-07-31 | Elan Pharma International Limited | Controlled release nanoparticulate compositions |
BR9915011A (pt) | 1998-11-03 | 2001-08-07 | Glaxo Group Ltd | Compostos, método para a preparação dos mesmos, composição farmacêutica, métodos de tratamento de um indivìduo humano ou animal sofrendo de uma condição que é mediada pela inibição seletiva de cox-2 e sofrendo de um distúrbio inflamatório, e, uso de um composto |
US6180136B1 (en) | 1998-11-10 | 2001-01-30 | Idexx Laboratories, Inc. | Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use |
WO2000030615A1 (en) | 1998-11-20 | 2000-06-02 | Rtp Pharma Inc. | Method of preparing stable suspensions of insoluble microparticles |
US6025683A (en) | 1998-12-23 | 2000-02-15 | Stryker Corporation | Motor control circuit for regulating a D.C. motor |
GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
JP2002538157A (ja) | 1999-02-27 | 2002-11-12 | グラクソ グループ リミテッド | ピラゾロピリジン |
GB9927844D0 (en) * | 1999-11-26 | 2000-01-26 | Glaxo Group Ltd | Chemical compounds |
ATE283048T1 (de) | 1999-12-08 | 2004-12-15 | Pharmacia Corp | Cyclooxygenase-2 hemmer enthaltende zusammensetzungen mit schnellem wirkungseintritt |
GB0003224D0 (en) * | 2000-02-11 | 2000-04-05 | Glaxo Group Ltd | Chemical compounds |
PT1294358E (pt) | 2000-06-28 | 2004-12-31 | Smithkline Beecham Plc | Processo de moagem por via humida |
GB0016877D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
CN1275964C (zh) | 2000-08-31 | 2006-09-20 | 霍夫曼-拉罗奇有限公司 | 作为细胞增殖抑制剂的7-氧代吡啶并嘧啶 |
GB0021494D0 (en) | 2000-09-01 | 2000-10-18 | Glaxo Group Ltd | Chemical comkpounds |
DE60237431D1 (de) | 2001-01-29 | 2010-10-07 | Univ Connecticut | Rezeptor-selektive cannabimimetische aminoalkylindole |
US7507767B2 (en) | 2001-02-08 | 2009-03-24 | Schering Corporation | Cannabinoid receptor ligands |
EP1361879A1 (en) | 2001-02-20 | 2003-11-19 | Bristol-Myers Squibb Company | 2,4-disubstituted pyrimidine-5-carboxamide derivatives as kcnq potassium channel modulators |
FR2839718B1 (fr) | 2002-05-17 | 2004-06-25 | Sanofi Synthelabo | Derives d'indole, leur procede de preparation et les compositions pharmaceutiques en contenant |
WO2004000807A1 (en) | 2002-06-19 | 2003-12-31 | Schering Corporation | Cannabinoid receptor agonists |
CA2490888C (en) | 2002-06-28 | 2011-05-24 | Yamanouchi Pharmaceutical Co., Ltd. | Diaminopyrimidinecarboxamide derivative |
UY27939A1 (es) * | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | Compuestos |
AU2003260436A1 (en) | 2002-08-21 | 2004-03-11 | Glaxo Group Limited | Pyrimidine compounds |
GB0222493D0 (en) | 2002-09-27 | 2002-11-06 | Glaxo Group Ltd | Compounds |
GB0222495D0 (en) | 2002-09-27 | 2002-11-06 | Glaxo Group Ltd | Compounds |
US7405221B2 (en) | 2002-09-27 | 2008-07-29 | Merck & Co., Inc. | Substituted pyrimidines |
AR043633A1 (es) | 2003-03-20 | 2005-08-03 | Schering Corp | Ligandos de receptores de canabinoides |
-
2003
- 2003-08-14 UY UY27939A patent/UY27939A1/es not_active Application Discontinuation
- 2003-08-19 AT AT07119063T patent/ATE489369T1/de not_active IP Right Cessation
- 2003-08-19 OA OA1200500052A patent/OA12910A/en unknown
- 2003-08-19 ES ES03792388T patent/ES2295682T3/es not_active Expired - Lifetime
- 2003-08-19 AT AT03792388T patent/ATE377591T1/de active
- 2003-08-19 DE DE60317348T patent/DE60317348T2/de not_active Expired - Lifetime
- 2003-08-19 NZ NZ537886A patent/NZ537886A/en unknown
- 2003-08-19 CA CA2495880A patent/CA2495880C/en not_active Expired - Fee Related
- 2003-08-19 EP EP07119063A patent/EP1878725B1/en not_active Expired - Lifetime
- 2003-08-19 EA EA200500392A patent/EA010130B1/ru not_active IP Right Cessation
- 2003-08-19 SI SI200331088T patent/SI1539712T1/sl unknown
- 2003-08-19 EP EP03792388A patent/EP1539712B1/en not_active Expired - Lifetime
- 2003-08-19 AP AP2005003219A patent/AP2005003219A0/xx unknown
- 2003-08-19 JP JP2004530220A patent/JP4583174B2/ja not_active Expired - Fee Related
- 2003-08-19 AU AU2003264076A patent/AU2003264076B2/en not_active Ceased
- 2003-08-19 UA UAA200501583A patent/UA83194C2/ru unknown
- 2003-08-19 KR KR1020057002813A patent/KR20050058367A/ko not_active Application Discontinuation
- 2003-08-19 US US10/524,470 patent/US7635701B2/en not_active Expired - Fee Related
- 2003-08-19 MY MYPI20033143A patent/MY137053A/en unknown
- 2003-08-19 DK DK03792388T patent/DK1539712T3/da active
- 2003-08-19 PL PL03376047A patent/PL376047A1/xx not_active Application Discontinuation
- 2003-08-19 EA EA200700934A patent/EA012703B1/ru not_active IP Right Cessation
- 2003-08-19 DE DE60335151T patent/DE60335151D1/de not_active Expired - Lifetime
- 2003-08-19 AR ARP030102997A patent/AR041016A1/es unknown
- 2003-08-19 BR BR0313676-0A patent/BR0313676A/pt not_active IP Right Cessation
- 2003-08-19 TW TW092122692A patent/TW200410946A/zh unknown
- 2003-08-19 MX MXPA05001960A patent/MXPA05001960A/es active IP Right Grant
- 2003-08-19 WO PCT/EP2003/009217 patent/WO2004018433A1/en active IP Right Grant
- 2003-08-19 CN CNB038241293A patent/CN100351239C/zh not_active Expired - Fee Related
- 2003-08-19 PE PE2003000839A patent/PE20040898A1/es not_active Application Discontinuation
- 2003-08-19 PT PT03792388T patent/PT1539712E/pt unknown
-
2005
- 2005-01-27 IL IL16655205A patent/IL166552A0/xx unknown
- 2005-02-01 ZA ZA200500913A patent/ZA200500913B/xx unknown
- 2005-02-18 EC EC2005005613A patent/ECSP055613A/es unknown
- 2005-03-07 MA MA28132A patent/MA27428A1/fr unknown
- 2005-03-17 IS IS7749A patent/IS7749A/is unknown
- 2005-03-18 NO NO20051451A patent/NO20051451D0/no not_active Application Discontinuation
- 2005-11-29 HK HK05110876A patent/HK1079193A1/xx not_active IP Right Cessation
-
2007
- 2007-08-27 IL IL185549A patent/IL185549A0/en unknown
-
2008
- 2008-01-31 CY CY20081100115T patent/CY1107871T1/el unknown
-
2009
- 2009-10-21 US US12/582,861 patent/US20100041654A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL166552A0 (en) | Pyrimidine derivatives and their use as cb2 modulators | |
SI1487805T1 (sl) | Pirimidinski derivati | |
AP2004003110A0 (en) | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives and their use as antibacterials | |
EP1546115A4 (en) | SUBSTITUTED PYRIMIDINES | |
AU2003266321A1 (en) | Tetrahydropyrimidine-2-one derivatives and their uses | |
TWI349671B (en) | Novel adenine derivative and its use | |
HK1091488A1 (en) | Pyrimidine derivatives | |
PL375390A1 (en) | 4-trifluoromethylpyrazolyl substituted pyridines and pyrimidines | |
PL375395A1 (en) | 4-trifluoromethylpyrazolyl substituted pyridines and pyrimidines | |
IL163940A0 (en) | Aryl substituted pyrimidines and the use thereof | |
AU2003249909A1 (en) | Phenoxypropenylphenyl derivatives and their use as herbicides | |
IL182136A0 (en) | Novel pyrimidine derivatives and their use as ppar-alpha modulators | |
IL163868A0 (en) | Hermiasterlin derivatives and uses thereof | |
AU2003202091A8 (en) | Guanidine derivatives | |
AU2003216221A1 (en) | Attachment and articles using same | |
GB0220214D0 (en) | Compounds and their use | |
AU2003206694A1 (en) | Substituted alkyl uracils and the use thereof | |
AU2003297612A8 (en) | 2-substituted-3-propenamide derivatives and methods of using the same | |
EP1553101A4 (en) | N-acetylglucosamine derivatives and their use | |
AU2002368112A1 (en) | Pyrimidine derivatives | |
AU2003215379A1 (en) | Substituted pyrimidinones and pyrimidinthiones | |
AU2003205963A8 (en) | Azaphenylalanine derivatives and their use as antithrombotic agents | |
GB0307231D0 (en) | 7-Nitroindoline derivatives and their uses | |
AU2003236937A1 (en) | School supply - universal | |
GB0227443D0 (en) | Pyrimidine derivatives |